Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Twelve years ago, while coaching in the Southeastern Conference at the University of Kentucky, his life took an unexpected ...

Multiple myeloma — cancer of the white blood cells known as plasma cells — can cause a vast spectrum of symptoms as it progresses. But multiple myeloma often has no outward signs in its early ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

An Essex mum left with holes in her spine after her cancer symptoms were put down to her pregnancy and post-partum recovery ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Help is now there for those diagnosed with hard-to-treat blood cancers like leukemia and lymphoma, as new therapies are ...